Amarin Corporation PLC (NASDAQ:AMRN) has been assigned a $10.00 target price by Cantor Fitzgerald in a research note issued to investors on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 206.75% from the stock’s current price.

Several other equities analysts have also recently commented on the stock. Zacks Investment Research raised shares of Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Monday, July 3rd. BidaskClub cut shares of Amarin Corporation PLC from a “buy” rating to a “hold” rating in a research report on Saturday, August 5th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research report on Thursday, June 1st. Finally, Jefferies Group LLC initiated coverage on shares of Amarin Corporation PLC in a research report on Thursday, June 29th. They issued a “reduce” rating and a $3.50 price target for the company. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $7.35.

Shares of Amarin Corporation PLC (NASDAQ AMRN) opened at 3.26 on Monday. The firm has a 50-day moving average price of $3.87 and a 200 day moving average price of $3.32. The stock’s market cap is $882.78 million. Amarin Corporation PLC has a 12-month low of $2.56 and a 12-month high of $4.47.

Amarin Corporation PLC (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. The company had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $40.35 million. The business’s revenue for the quarter was up 37.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.07) EPS. Equities research analysts expect that Amarin Corporation PLC will post ($0.22) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/14/amarin-corporation-plc-nasdaqamrn-pt-set-at-10-00-by-cantor-fitzgerald.html.

In related news, General Counsel Joseph T. Kennedy sold 307,911 shares of Amarin Corporation PLC stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $4.00, for a total transaction of $1,231,644.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 3.72% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in the company. Wells Fargo & Company MN raised its stake in shares of Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares in the last quarter. Perkins Capital Management Inc. bought a new stake in shares of Amarin Corporation PLC during the first quarter valued at approximately $110,000. JPMorgan Chase & Co. raised its stake in shares of Amarin Corporation PLC by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 7,580 shares in the last quarter. Charlemagne Capital Ltd. bought a new stake in shares of Amarin Corporation PLC during the fourth quarter valued at approximately $116,000. Finally, Private Advisor Group LLC raised its stake in shares of Amarin Corporation PLC by 42.6% in the fourth quarter. Private Advisor Group LLC now owns 49,138 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 14,683 shares in the last quarter. Hedge funds and other institutional investors own 37.60% of the company’s stock.

Amarin Corporation PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.